文献速递银屑病与炎症性皮肤病

乌司奴单抗注射后4周浓度与银屑病临床应答相关

Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis.
PubMed 文献 · Br J Dermatol · 2019-07-24

BACKGROUND: Cost-effective use of biologicals is important. As drug concentrations have been linked to clinical outcomes, monitoring drug concentrations is a valuable tool to guide clinical decision-making.…

要点

  • 注射后4周乌司奴单抗浓度与绝对PASI评分呈显著负相关。
  • 最佳应答者(PASI≤2)浓度高于次优应答者(PASI>2)。

核心结论

  • 乌司奴单抗注射后4周存在浓度-应答关系,监测该时间点浓度可及时识别暴露不足、可能从治疗优化中获益的患者。

主要发现

  • 仅1例患者(2%)检出抗乌司奴单抗抗体。

临床怎么用

  • 可考虑监测乌司奴单抗注射后4周血清浓度,以识别暴露不足且可能从治疗优化中获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cost-effective use of biologicals is important. As drug concentrations have been linked to clinical outcomes, monitoring drug concentrations is a valuable tool to guide clinical decision-making. A concentration-response relationship for ustekinumab at trough is uncertain owing to the contradictory results reported. OBJECTIVES: To investigate the relationship between 4-week postinjection ustekinumab concentrations and clinical response in patients with psoriasis. METHODS: Forty-nine patients with moderate-to-severe psoriasis treated with 45 mg or 90 mg ustekinumab every 12 weeks for ≥ 16 weeks were included. Ustekinumab serum concentrations and anti-ustekinumab antibodies were measured at week 4 after injection and disease severity was assessed by Psoriasis Area and Severity Index (PASI). RESULTS: At week 4 after injection, a significantly negative correlation was observed between ustekinumab concentrations and absolute PASI score up to 5·9 μg mL-1 (ρ = -0·357, P = 0·032). Ustekinumab concentrations were higher in optimal responders (PASI ≤ 2) than in suboptimal responders (PASI > 2) (4·0 vs 2·8 μg mL-1 , P = 0·036). The ustekinumab concentration threshold associated with optimal response was determined to be 3·6 μg mL-1 (area under the curve 0·71, sensitivity 86%, specificity 63%). Only one patient (2%) had anti-ustekinumab antibodies. Psoriatic arthritis was identified as an independent predictor of higher PASI scores and higher ustekinumab concentrations (P = 0·003 and P = 0·048, respectively). CONCLUSIONS: A concentration-response relationship at week 4 after injection was observed for patients with psoriasis treated with ustekinumab. Monitoring 4-week postinjection ustekinumab concentrations could timely identify underexposed patients who might benefit from treatment optimization. What's already known about this topic? Monitoring drug concentrations is a valuable tool that can guide clinical decision-making when drug concentrations are linked to clinical outcomes. The presence of a concentration-response relationship for ustekinumab at trough is still debated owing to the contradictory results reported. What does this study add? A concentration-response relationship at week 4 after injection for ustekinumab-treated patients with psoriasis was demonstrated. Monitoring 4-week postinjection ustekinumab concentrations could timely identify underexposed patients who might benefit from treatment optimization. Based on the findings of this study, a treatment algorithm for patients with a suboptimal response is proposed.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Van den Berghe N, De Keyser E, Soenen R, et al. Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis. Br J Dermatol. 2019. PMID: 31004510. doi:10.1111/bjd.18016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。